NCT06925854View on ClinicalTrials.gov

A Study to Investigate How AZD4144 Affects the Pharmacokinetics of Rosuvastatin in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 17, 2025

Primary Completion Date

June 12, 2025

Study Completion Date

June 12, 2025

Conditions
Healthy
Interventions
DRUG

AZD4144

Oral tablet of AZD4144 will be administered.

DRUG

Rosuvastatin

Oral tablet of rosuvastatin will be administered.

Trial Locations (1)

HA1 3UJ

Research Site, Harrow

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT06925854 - A Study to Investigate How AZD4144 Affects the Pharmacokinetics of Rosuvastatin in Healthy Participants | Biotech Hunter | Biotech Hunter